APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pharmaceutical Contract Development and Manufacturing Organization

A pharmaceutical CDMO provides contracted drug-development and manufacturing services, including process development, analytical work and production of drug substances or finished dosage forms.

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pharmaceutical Contract Development and Manufacturing Organization Market Outlook and Growth Opportunities 2026

Report ID 17421425041 January 2026205 pages

Choose your research edition.

Industry ResearchPharmaceutical Contract Development and Manufacturing Organization Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmaceutical Contract Development and Manufacturing Organization Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Pharmaceutical Contract Development and Manufacturing Organization Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmaceutical Contract Development and Manufacturing Organization Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmaceutical Contract Development and Manufacturing Organization Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Pharmaceutical Contract Development and Manufacturing Organization market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pharmaceutical Contract Development and Manufacturing Organization is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pharmaceutical Contract Development and Manufacturing Organization is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pharmaceutical Contract Development and Manufacturing Organization is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pharmaceutical Contract Development and Manufacturing Organization market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pharmaceutical Contract Development and Manufacturing Organization market include Catalent, Recipharm, Jubilant Life Sciences, Patheon Inc., Boehringer Ingelheim, Pfizer Centreone, Aenova Group, Famar and Baxter Pharmaceutical Solutions, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pharmaceutical Contract Development and Manufacturing Organization market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pharmaceutical Contract Development and Manufacturing Organization and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pharmaceutical Contract Development and Manufacturing Organization revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pharmaceutical Contract Development and Manufacturing Organization market.

Pharmaceutical Contract Development and Manufacturing Organization Segment by Company

Catalent

Recipharm

Jubilant Life Sciences

Patheon Inc.

Boehringer Ingelheim

Pfizer Centreone

Aenova Group

Famar

Baxter Pharmaceutical Solutions

Lonza Group

Tesa Labtec

Tapemark

ARX LLC

Cambrex

Samsung Biologics

Fujifilm Diosynth Biotechnologies

WuXi Biologics

Center for Breakthrough Medicines (CBM)

Siegfried AG

Pharmaceutical Contract Development and Manufacturing Organization Segment by Type

API Development

Pharmaceutical Manufacturing

Pharmaceutical Contract Development and Manufacturing Organization Segment by Application

Large Enterprise

SME

Pharmaceutical Contract Development and Manufacturing Organization Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pharmaceutical Contract Development and Manufacturing Organization status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pharmaceutical Contract Development and Manufacturing Organization key companies, revenue, market share, and recent developments.

3. To split the Pharmaceutical Contract Development and Manufacturing Organization breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pharmaceutical Contract Development and Manufacturing Organization market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pharmaceutical Contract Development and Manufacturing Organization significant trends, drivers, influence factors in global and regions.

6. To analyze Pharmaceutical Contract Development and Manufacturing Organization competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmaceutical Contract Development and Manufacturing Organization market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmaceutical Contract Development and Manufacturing Organization and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmaceutical Contract Development and Manufacturing Organization.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pharmaceutical Contract Development and Manufacturing Organization industry.

Chapter 3: Detailed analysis of Pharmaceutical Contract Development and Manufacturing Organization company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pharmaceutical Contract Development and Manufacturing Organization in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pharmaceutical Contract Development and Manufacturing Organization in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pharmaceutical Contract Development and Manufacturing Organization Industry Trends Table 2. Pharmaceutical Contract Development and Manufacturing Organization Industry Drivers Table 3. Pharmaceutical Contract Development and Manufacturing Organization Industry Opportunities and Challenges Table 4. Pharmaceutical Contract Development and Manufacturing Organization Industry Restraints Table 5. Global Pharmaceutical Contract Development and Manufacturing Organization Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pharmaceutical Contract Development and Manufacturing Organization Revenue Share by Company (2021-2026) Table 7. Global Pharmaceutical Contract Development and Manufacturing Organization Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pharmaceutical Contract Development and Manufacturing Organization Key Company Manufacturing Base & Headquarters Table 9. Global Pharmaceutical Contract Development and Manufacturing Organization Company, Product Type & Application Table 10. Global Pharmaceutical Contract Development and Manufacturing Organization Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pharmaceutical Contract Development and Manufacturing Organization by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of API Development Table 15. Significant Companies of Pharmaceutical Manufacturing Table 16. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type (2021-2026) Table 20. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Large Enterprise Table 22. Significant Companies of SME Table 23. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application (2021-2026) Table 27. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application (2027-2032) Table 28. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Region (2021-2026) Table 31. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Region (2027-2032) Table 33. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Market Share by Country (2021-2026) Table 36. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Market Share by Country (2027-2032) Table 38. Catalent Company Information Table 39. Catalent Business Overview Table 40. Catalent Pharmaceutical Contract Development and Manufacturing Organization Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Catalent Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 42. Catalent Recent Development Table 43. Recipharm Company Information Table 44. Recipharm Business Overview Table 45. Recipharm Pharmaceutical Contract Development and Manufacturing Organization Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Recipharm Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 47. Recipharm Recent Development Table 48. Jubilant Life Sciences Company Information Table 49. Jubilant Life Sciences Business Overview Table 50. Jubilant Life Sciences Pharmaceutical Contract Development and Manufacturing Organization Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Jubilant Life Sciences Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 52. Jubilant Life Sciences Recent Development Table 53. Patheon Inc. Company Information Table 54. Patheon Inc. Business Overview Table 55. Patheon Inc. Pharmaceutical Contract Development and Manufacturing Organization Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Patheon Inc. Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 57. Patheon Inc. Recent Development Table 58. Boehringer Ingelheim Company Information Table 59. Boehringer Ingelheim Business Overview Table 60. Boehringer Ingelheim Pharmaceutical Contract Development and Manufacturing Organization Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Boehringer Ingelheim Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 62. Boehringer Ingelheim Recent Development Table 63. Pfizer Centreone Company Information Table 64. Pfizer Centreone Business Overview Table 65. Pfizer Centreone Pharmaceutical Contract Development and Manufacturing Organization Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Pfizer Centreone Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 67. Pfizer Centreone Recent Development Table 68. Aenova Group Company Information Table 69. Aenova Group Business Overview Table 70. Aenova Group Pharmaceutical Contract Development and Manufacturing Organization Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Aenova Group Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 72. Aenova Group Recent Development Table 73. Famar Company Information Table 74. Famar Business Overview Table 75. Famar Pharmaceutical Contract Development and Manufacturing Organization Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Famar Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 77. Famar Recent Development Table 78. Baxter Pharmaceutical Solutions Company Information Table 79. Baxter Pharmaceutical Solutions Business Overview Table 80. Baxter Pharmaceutical Solutions Pharmaceutical Contract Development and Manufacturing Organization Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Baxter Pharmaceutical Solutions Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 82. Baxter Pharmaceutical Solutions Recent Development Table 83. Lonza Group Company Information Table 84. Lonza Group Business Overview Table 85. Lonza Group Pharmaceutical Contract Development and Manufacturing Organization Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Lonza Group Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 87. Lonza Group Recent Development Table 88. Tesa Labtec Company Information Table 89. Tesa Labtec Business Overview Table 90. Tesa Labtec Pharmaceutical Contract Development and Manufacturing Organization Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Tesa Labtec Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 92. Tesa Labtec Recent Development Table 93. Tapemark Company Information Table 94. Tapemark Business Overview Table 95. Tapemark Pharmaceutical Contract Development and Manufacturing Organization Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Tapemark Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 97. Tapemark Recent Development Table 98. ARX LLC Company Information Table 99. ARX LLC Business Overview Table 100. ARX LLC Pharmaceutical Contract Development and Manufacturing Organization Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. ARX LLC Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 102. ARX LLC Recent Development Table 103. Cambrex Company Information Table 104. Cambrex Business Overview Table 105. Cambrex Pharmaceutical Contract Development and Manufacturing Organization Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Cambrex Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 107. Cambrex Recent Development Table 108. Samsung Biologics Company Information Table 109. Samsung Biologics Business Overview Table 110. Samsung Biologics Pharmaceutical Contract Development and Manufacturing Organization Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Samsung Biologics Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 112. Samsung Biologics Recent Development Table 113. Fujifilm Diosynth Biotechnologies Company Information Table 114. Fujifilm Diosynth Biotechnologies Business Overview Table 115. Fujifilm Diosynth Biotechnologies Pharmaceutical Contract Development and Manufacturing Organization Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Fujifilm Diosynth Biotechnologies Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 117. Fujifilm Diosynth Biotechnologies Recent Development Table 118. WuXi Biologics Company Information Table 119. WuXi Biologics Business Overview Table 120. WuXi Biologics Pharmaceutical Contract Development and Manufacturing Organization Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. WuXi Biologics Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 122. WuXi Biologics Recent Development Table 123. Center for Breakthrough Medicines (CBM) Company Information Table 124. Center for Breakthrough Medicines (CBM) Business Overview Table 125. Center for Breakthrough Medicines (CBM) Pharmaceutical Contract Development and Manufacturing Organization Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Center for Breakthrough Medicines (CBM) Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 127. Center for Breakthrough Medicines (CBM) Recent Development Table 128. Siegfried AG Company Information Table 129. Siegfried AG Business Overview Table 130. Siegfried AG Pharmaceutical Contract Development and Manufacturing Organization Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Siegfried AG Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio Table 132. Siegfried AG Recent Development Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Pharmaceutical Contract Development and Manufacturing Organization Product Image Figure 2. Global Pharmaceutical Contract Development and Manufacturing Organization Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmaceutical Contract Development and Manufacturing Organization Market Size (2021-2032) & (US$ Million) Figure 4. Global Pharmaceutical Contract Development and Manufacturing Organization Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. API Development Image Figure 8. Pharmaceutical Manufacturing Image Figure 9. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type (2021-2032) Figure 12. Large Enterprise Image Figure 13. SME Image Figure 14. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application (2021-2032) Figure 17. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Pharmaceutical Contract Development and Manufacturing Organization Sales Value (2021-2032) & (US$ Million) Figure 20. North America Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Pharmaceutical Contract Development and Manufacturing Organization Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Pharmaceutical Contract Development and Manufacturing Organization Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Pharmaceutical Contract Development and Manufacturing Organization Sales Value (2021-2032) & (US$ Million) Figure 26. South America Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • API Development
  • Pharmaceutical Manufacturing
Applications
  • Large Enterprise
  • SME
Companies covered
  • Catalent
  • Recipharm
  • Jubilant Life Sciences
  • Patheon Inc.
  • Boehringer Ingelheim
  • Pfizer Centreone
  • Aenova Group
  • Famar
  • Baxter Pharmaceutical Solutions
  • Lonza Group
  • Tesa Labtec
  • Tapemark
  • ARX LLC
  • Cambrex
  • Samsung Biologics
  • Fujifilm Diosynth Biotechnologies
  • WuXi Biologics
  • Center for Breakthrough Medicines (CBM)
  • Siegfried AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pharmaceutical Contract Development and Manufacturing Organization Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pharmaceutical Contract Development and Manufacturing Organization Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pharmaceutical Contract Development and Manufacturing Organization Market Dynamics
  1. 2.1 Pharmaceutical Contract Development and Manufacturing Organization Industry Trends
  2. 2.2 Pharmaceutical Contract Development and Manufacturing Organization Industry Drivers
  3. 2.3 Pharmaceutical Contract Development and Manufacturing Organization Industry Opportunities and Challenges
  4. 2.4 Pharmaceutical Contract Development and Manufacturing Organization Industry Restraints
3 Pharmaceutical Contract Development and Manufacturing Organization Market by Company
  1. 3.1 Global Pharmaceutical Contract Development and Manufacturing Organization Company Revenue Ranking in 2025
  2. 3.2 Global Pharmaceutical Contract Development and Manufacturing Organization Revenue by Company (2021-2026)
  3. 3.3 Global Pharmaceutical Contract Development and Manufacturing Organization Company Ranking (2024-2026)
  4. 3.4 Global Pharmaceutical Contract Development and Manufacturing Organization Company Manufacturing Base and Headquarters
  5. 3.5 Global Pharmaceutical Contract Development and Manufacturing Organization Company Product Type and Application
  6. 3.6 Global Pharmaceutical Contract Development and Manufacturing Organization Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pharmaceutical Contract Development and Manufacturing Organization Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pharmaceutical Contract Development and Manufacturing Organization Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pharmaceutical Contract Development and Manufacturing Organization Market by Type
  1. 4.1 Pharmaceutical Contract Development and Manufacturing Organization Type Introduction
  2. 4.1.1 API Development
  3. 4.1.2 Pharmaceutical Manufacturing
  4. 4.2 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Type
  5. 4.2.1 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Type (2021-2032)
  7. 4.2.3 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type (2021-2032)
5 Pharmaceutical Contract Development and Manufacturing Organization Market by Application
  1. 5.1 Pharmaceutical Contract Development and Manufacturing Organization Application Introduction
  2. 5.1.1 Large Enterprise
  3. 5.1.2 SME
  4. 5.2 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Application
  5. 5.2.1 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Application (2021-2032)
  7. 5.2.3 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application (2021-2032)
6 Pharmaceutical Contract Development and Manufacturing Organization Regional Value Analysis
  1. 6.1 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pharmaceutical Contract Development and Manufacturing Organization Sales Value (2021-2032)
  7. 6.3.2 North America Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pharmaceutical Contract Development and Manufacturing Organization Sales Value (2021-2032)
  10. 6.4.2 Europe Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Organization Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pharmaceutical Contract Development and Manufacturing Organization Sales Value (2021-2032)
  16. 6.6.2 South America Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Country, 2025 VS 2032
7 Pharmaceutical Contract Development and Manufacturing Organization Country-level Value Analysis
  1. 7.1 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pharmaceutical Contract Development and Manufacturing Organization Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pharmaceutical Contract Development and Manufacturing Organization Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pharmaceutical Contract Development and Manufacturing Organization Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Catalent
  2. 8.1.1 Catalent Company Information
  3. 8.1.2 Catalent Business Overview
  4. 8.1.3 Catalent Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Catalent Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  6. 8.1.5 Catalent Recent Developments
  7. 8.2 Recipharm
  8. 8.2.1 Recipharm Company Information
  9. 8.2.2 Recipharm Business Overview
  10. 8.2.3 Recipharm Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Recipharm Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  12. 8.2.5 Recipharm Recent Developments
  13. 8.3 Jubilant Life Sciences
  14. 8.3.1 Jubilant Life Sciences Company Information
  15. 8.3.2 Jubilant Life Sciences Business Overview
  16. 8.3.3 Jubilant Life Sciences Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Jubilant Life Sciences Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  18. 8.3.5 Jubilant Life Sciences Recent Developments
  19. 8.4 Patheon Inc.
  20. 8.4.1 Patheon Inc. Company Information
  21. 8.4.2 Patheon Inc. Business Overview
  22. 8.4.3 Patheon Inc. Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Patheon Inc. Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  24. 8.4.5 Patheon Inc. Recent Developments
  25. 8.5 Boehringer Ingelheim
  26. 8.5.1 Boehringer Ingelheim Company Information
  27. 8.5.2 Boehringer Ingelheim Business Overview
  28. 8.5.3 Boehringer Ingelheim Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Boehringer Ingelheim Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  30. 8.5.5 Boehringer Ingelheim Recent Developments
  31. 8.6 Pfizer Centreone
  32. 8.6.1 Pfizer Centreone Company Information
  33. 8.6.2 Pfizer Centreone Business Overview
  34. 8.6.3 Pfizer Centreone Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Centreone Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  36. 8.6.5 Pfizer Centreone Recent Developments
  37. 8.7 Aenova Group
  38. 8.7.1 Aenova Group Company Information
  39. 8.7.2 Aenova Group Business Overview
  40. 8.7.3 Aenova Group Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Aenova Group Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  42. 8.7.5 Aenova Group Recent Developments
  43. 8.8 Famar
  44. 8.8.1 Famar Company Information
  45. 8.8.2 Famar Business Overview
  46. 8.8.3 Famar Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Famar Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  48. 8.8.5 Famar Recent Developments
  49. 8.9 Baxter Pharmaceutical Solutions
  50. 8.9.1 Baxter Pharmaceutical Solutions Company Information
  51. 8.9.2 Baxter Pharmaceutical Solutions Business Overview
  52. 8.9.3 Baxter Pharmaceutical Solutions Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Baxter Pharmaceutical Solutions Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  54. 8.9.5 Baxter Pharmaceutical Solutions Recent Developments
  55. 8.10 Lonza Group
  56. 8.10.1 Lonza Group Company Information
  57. 8.10.2 Lonza Group Business Overview
  58. 8.10.3 Lonza Group Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lonza Group Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  60. 8.10.5 Lonza Group Recent Developments
  61. 8.11 Tesa Labtec
  62. 8.11.1 Tesa Labtec Company Information
  63. 8.11.2 Tesa Labtec Business Overview
  64. 8.11.3 Tesa Labtec Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Tesa Labtec Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  66. 8.11.5 Tesa Labtec Recent Developments
  67. 8.12 Tapemark
  68. 8.12.1 Tapemark Company Information
  69. 8.12.2 Tapemark Business Overview
  70. 8.12.3 Tapemark Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Tapemark Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  72. 8.12.5 Tapemark Recent Developments
  73. 8.13 ARX LLC
  74. 8.13.1 ARX LLC Company Information
  75. 8.13.2 ARX LLC Business Overview
  76. 8.13.3 ARX LLC Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  77. 8.13.4 ARX LLC Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  78. 8.13.5 ARX LLC Recent Developments
  79. 8.14 Cambrex
  80. 8.14.1 Cambrex Company Information
  81. 8.14.2 Cambrex Business Overview
  82. 8.14.3 Cambrex Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Cambrex Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  84. 8.14.5 Cambrex Recent Developments
  85. 8.15 Samsung Biologics
  86. 8.15.1 Samsung Biologics Company Information
  87. 8.15.2 Samsung Biologics Business Overview
  88. 8.15.3 Samsung Biologics Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Samsung Biologics Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  90. 8.15.5 Samsung Biologics Recent Developments
  91. 8.16 Fujifilm Diosynth Biotechnologies
  92. 8.16.1 Fujifilm Diosynth Biotechnologies Company Information
  93. 8.16.2 Fujifilm Diosynth Biotechnologies Business Overview
  94. 8.16.3 Fujifilm Diosynth Biotechnologies Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Fujifilm Diosynth Biotechnologies Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  96. 8.16.5 Fujifilm Diosynth Biotechnologies Recent Developments
  97. 8.17 WuXi Biologics
  98. 8.17.1 WuXi Biologics Company Information
  99. 8.17.2 WuXi Biologics Business Overview
  100. 8.17.3 WuXi Biologics Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  101. 8.17.4 WuXi Biologics Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  102. 8.17.5 WuXi Biologics Recent Developments
  103. 8.18 Center for Breakthrough Medicines (CBM)
  104. 8.18.1 Center for Breakthrough Medicines (CBM) Company Information
  105. 8.18.2 Center for Breakthrough Medicines (CBM) Business Overview
  106. 8.18.3 Center for Breakthrough Medicines (CBM) Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Center for Breakthrough Medicines (CBM) Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  108. 8.18.5 Center for Breakthrough Medicines (CBM) Recent Developments
  109. 8.19 Siegfried AG
  110. 8.19.1 Siegfried AG Company Information
  111. 8.19.2 Siegfried AG Business Overview
  112. 8.19.3 Siegfried AG Pharmaceutical Contract Development and Manufacturing Organization Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Siegfried AG Pharmaceutical Contract Development and Manufacturing Organization Product Portfolio
  114. 8.19.5 Siegfried AG Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst